International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064

Downloads: 2 | Views: 66 | Weekly Hits: ⮙2 | Monthly Hits: ⮙2

Doctoral Thesis | Pharmacotherapeutics | India | Volume 12 Issue 1, January 2023

Real World Studies on Undesirable Effects of Some Antithrombotic Drugs in a Tertiary Care Hospital

Mudigonda Sai Krishna

Abstract: Background: Hemostasis is the cessation of blood loss from a damaged vessel. Platelets first adhere to macromolecules in the sub endothelial regions of the injured blood vessel, where they become activated. Adherent platelets release substances that activate nearby platelets, thereby recruiting them to the site of injury. Activated platelet aggregate to form the primary hemostatic plug. Methods and Materials: It is a hospital based prospective observational study in the inpatient departments of cardiology and neurology for a period of six months. Total 92 patients are included in the study under the guidance of physician. Results: It was a prospective observational study in which total 92 patients were included. Most commonly prescribed drugs were heparin, aspirin and clopidogrel and aspirin-clopidogrel combination which is seen in most of the following diagnosis like myocardial infarction, coronary artery disease, acute coronary syndrome with undesirable side effects like thrombocytopenia, prolonged bleeding, heart burn and tachycardia. Conclusion: Most common drug is heparin which is 50% of the patients. Aspirin 43% mainly for coronary artery disease and myocardial infarction. Remaining 7% either clopidogrel or aspirin-clopidogrel combination (dual therapy).

Keywords: Myocardial infarction, Coronary Artery Disease, Acute Coronary Syndrome, Hemostasis, Heparin

Edition: Volume 12 Issue 1, January 2023,

Pages: 231 - 234

How to Download this Article?

Type Your Valid Email Address below to Receive the Article PDF Link

Verification Code will appear in 2 Seconds ... Wait